Remove 2024 Remove Communication Remove Compounding Remove FDA
article thumbnail

Top Performing Drug of 2021 - Trulicity (February Edition)

PharmaShots

Some of its FDA-approved competitors include: Patents7 Eli Lilly carries big expectations from Trulicity to boost its revenue. In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026). In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026).

article thumbnail

PharmaShots' Key Highlights of First Quarter 2023

PharmaShots

It now offers DPN patients relief from chronic pain through low doses of stimulation & the battery lasts up to 10 years at low-dose settings The system also pairs with Abbott’s NeuroSphere Virtual Clinic, a connected care app for people to communicate with a physician and receive remote treatment adjustments. ORR (41.8%

FDA 40
article thumbnail

AlgoTx unveils plans for Phase II trial for rare chronic condition

Pharmaceutical Technology

AlgoTx remains on track to start enrolling subjects of a Phase II study of its compound ATX01 for the rare condition erythromelalgia in Q2 2023, says CEO Stéphane Thiroloix. In June 2020, the FDA gave ATX01 an orphan drug designation in erythromelalgia. Free Report How is the Biopharmaceutical industry evolving?